ArticleFrontiers in neurology2022
Effect of a Drug-Eluting Stent vs. Bare Metal Stent for the Treatment of Symptomatic Intracranial and Vertebral Artery Stenosis.
Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Comparison of angioplasty, stents and conventional medical therapy for symptomatic intracranial atherosclerosis: a network meta-analysis.Frontiers in neurology · 2026Pooled it
- Drug-eluting stent versus bare metal stent for symptomatic intracranial stenosis: a comparative systematic review and meta-analysis study.European journal of clinical pharmacology · 2025Pooled it
- Efficacy and safety of drug-eluting stents versus bare-metal stents in symptomatic intracranial and vertebral artery stenosis: a meta-analysis.Frontiers in neurology · 2024Pooled it
- Safety and efficacy of stenting for symptomatic intracranial artery stenosis: a systematic reveiw and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Stent angioplasty in patients with vertebral artery ostial stenosis: clinical and angiographic outcomes in 525 patients.Stroke and vascular neurology · 2026Article
- Sirolimus Drug-Eluting Stent (DES) in vertebral artery ostial stenosis: insights from a multicenter analysis.Neuroradiology · 2026Article
- Drug-eluting stents versus bare-metal stents in the treatment of drug-refractory intracranial atherosclerotic disease: a retrospective single-center comparison.CVIR endovascular · 2026Article
- Dedicated drug-eluting stents versus bare-metal stents for vertebral artery origin stenosis: a real-world single-center experience.BMC neurology · 2025Observational
- One-year outcomes of the drug eluting stent in the treatment of severe vertebral artery ostium stenosis: single-center experience.Neurosurgical review · 2025Article
- Interventional Radiology Management of Renal Artery Stenosis After Kidney Transplant: Single-Center Experience and Management Strategies.Diagnostics (Basel, Switzerland) · 2025Article
- Elucidating the benefit of drug-eluting stent for symptomatic intracranial atherosclerotic stenosis: Meta-analysis of randomized controlled trials.Surgical neurology international · 2025Review
- Comparison of safety and efficacy of different endovascular treatments for symptomatic intracranial atherosclerotic stenosis: results from a single center.Frontiers in neurology · 2025Article
- Intracranial stenting with the Neuroform Atlas Stent for symptomatic intracranial atherosclerotic stenosis: a bi-center retrospective analysis including stroke recurrence nomogram.Frontiers in neurology · 2025Article
- Safety and efficacy of extracranial vertebral artery stenting in elderly patients with symptomatic vertebral artery stenosis.Frontiers in aging neuroscience · 2025Article
- Net meta-analysis: comparison of bare metal stent, drug-coated balloon and drug-eluting stent in the treatment of cerebral arterial stenosis.Frontiers in neurology · 2025Review
- Endovascular treatment of symptomatic severe intracranial atherosclerotic stenosis with a novel intracranial dedicated drug-eluting stent: a more effective treatment approach.Frontiers in neurology · 2024Article
- Electrochemical peptide nucleic acid functionalized α-FeMikrochimica acta · 2023Article
- Percutaneous angioplasty and/or stenting versus aggressive medical therapy in patients with symptomatic intracranial atherosclerotic stenosis: a 1-year follow-up study.Frontiers in aging neuroscience · 2023Article
- Long-term outcome and factors associated with restenosis after combination therapy of balloon angioplasty and stenting for symptomatic intracranial stenosis.BMC neurology · 2022Article
- Clinical efficacy of drug-eluting stents in the treatment of vertebral artery stenosis and analysis of factors contributing to stent restenosis.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For patients with symptomatic intracranial and vertebral artery stenosis who receive endovascular treatment, in-stent restenosis (ISR) is associated with the recurrence of ischemic stroke. This study evaluated a drug-eluting stent (DES) vs. bare metal stent (BMS) for the treatment of symptomatic intracranial and vertebral artery stenosis. Methods: The trial was a multicenter, 1:1 randomized, prospective feasibility clinical trial with 10 participating centers in China from March 2014 to October 2015. Eligible patients had symptomatic intracranial and vertebral artery stenosis (70%-99%) and had medical drug treatment failure. The primary endpoint was the rate of in-stent restenosis at 180 days of randomization. The secondary endpoint was a composite of the following two outcomes: (1) ischemic stroke or transient cerebral ischemia (TIA) in the same territory as the presenting event (distal to the target lesion) between 30 days and 1 year after randomization and (2) successful stent implantation. The safety outcome was the presence of stroke in any territory and death within 30 days of randomization or adverse events. Group Results: We enrolled 188 patients at 10 medical centers in China (92 assigned to the DES group and 96 to the BMS group). The mean age of the 188 study participants was 61.6 years (range, 38-75 years); 152 participants (80.9%) were male. There were 28 patients (43.8%) with an ISR at 180 days in the BMS group and 10 patients (14.5%) in the DES group [risk difference, 29.3% (95% CI, 14.5%-44.0%); Conclusions: Among patients with symptomatic intracranial arterial stenosis and vertebral artery stenosis, the use of a drug-eluting stent compared with a bare metal stent resulted in a decreased risk of ISR, similar successful stent implantation, and similar adverse events. These findings support the use of a drug-eluting stent for patients with symptomatic intracranial arterial stenosis and vertebral artery stenosis. Clinical Trial Registration: http://www.chictr.org.cn/showproj.aspx?proj=148272, identifier: ChiCTR2200055925.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.